Missing Script

Get updates

Evidence Explorer / MS-N201 / Supportive physical care / Appraised November 1, 2026

A large open-label randomized trial in people at higher risk of acute radiation dermatitis found fewer grade 2 or 3 reactions with Mepitel Film than with standard skin care. The result concerns skin toxicity—not tumor response—and depends on correct application of a specific film.

Evidence at a glance

  • Population: people receiving breast or chest-wall radiotherapy after lumpectomy with large breasts or after mastectomy.
  • Analyzed: 376 participants in the modified intention-to-treat population; 251 film and 125 standard care.
  • Primary result: grade 2–3 dermatitis 15.5% vs 45.6% (odds ratio 0.20; P<.0001).
  • Other results: grade 3 dermatitis 2.8% vs 13.6%; moist desquamation 8.0% vs 19.2%.
  • Evidence label: promising randomized evidence with open-label limitations.

What was studied

The phase III trial randomized participants 2:1 to Mepitel Film or standard care. The reported odds ratio for grade 3 dermatitis was 0.19; for moist desquamation it was 0.36. These are substantial absolute differences in a selected higher-risk population.

Two participants developed rash and one had severe itching that led to early film removal. Application quality, anatomical folds, sweating and local radiotherapy practices may affect performance.

What this evidence cannot establish

Patients and care teams could see the film, so grading and supportive-care behavior may have been influenced by lack of blinding. The population was enriched for higher dermatitis risk, which may limit generalizability to lower-risk breast radiotherapy.

This record does not establish that every transparent film is interchangeable with Mepitel or that the film treats established infection or skin breakdown.

Practical safety context

Radiation skin reactions still require clinical assessment. Film should not conceal infection, rapidly spreading redness, fever, drainage or wound separation.

Ask who will apply and replace it, what to do if it rolls or traps moisture, and when it should be removed because of rash, itching or pain.

Questions for the care team

  • Am I in a higher-risk group similar to the trial population?
  • Does this radiation service have experience with the exact film and application schedule?
  • How will dermatitis be graded, and what symptoms require urgent review?

Sources

Source note: PubMed metadata, the original report and registry entry were checked; detailed extraction was limited to the accessible abstract and registry fields. Funding and conflict information is reported only where it was available in the checked source. No correction, retraction or expression of concern was identified in the PubMed-linked record on November 1, 2026.

This record is educational. It is not a personal treatment recommendation and does not replace advice from the oncology or radiation-care team. Symptom or toxicity outcomes do not demonstrate tumor response, recurrence prevention or longer survival.